A Phase 4 interventional study of Palbociclib and Letrozole in Breast Cancer, sponsored by Pfizer. Completed at 34 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-27.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.
Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 26th largest by enrollment, is one of 15 that started in 2016, is one of 5 in phase 4, and was the 35th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
American Society of Clinical Oncology · Sites in United States
Ages 60+
Region Örebro County · Sites in Finland, Greece, Italy and 3 more countries
Ages 70+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+ · Women only
Northwestern University · Sites in United States
Ages 18+
By country, each count listing its studies:
palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, palbociclib is the treatment under test here. Read study by study →
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 68 · Phase 3 21 · Phase 4 5
First in 2008; this study’s year is marked. 15 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 111 interventional studies. Of the 54 that completed or were terminated, 27 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 111 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 28th largest by enrollment of the 121 interventional ones that give a count, is one of 6 that started in 2016, is one of 3 in phase 4, and was the 91st registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
13 of the studies testing palbociclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT02605486Memorial Sloan Kettering Cancer CenterPalbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | 2026-11 |
| NCT02738866Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPalbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | 2026-12 |
| NCT07130643Xinhong Wu, PhDEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer | 2026-12-20 |
| NCT03573648Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 111 studies testing palbociclib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate.
To provide access to palbociclib to post-menopausal patients with hormone receptor-positive [HR(+)], HER2-negative [HER2(-)] ABC who are deemed appropriate for letrozole therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Palbociclib plus Letrozole
Drug: Palbociclib · Drug: Letrozole
125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
Also known as: IBRANCE
2.5 mg/d tablets orally on a continuous regimen
Number of Participants With Treatment-Emergent Adverse Events (All Causalities)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as treatment emergent adverse events (TEAEs). AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
Number of Participants With Treatment-Emergent Adverse Events by Severity (All Causalities)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.
Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
Number of Participants With Treatment-Emergent Adverse Events (Palbociclib-Related)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Palbociclib-related TEAEs were determined by the investigator.
Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
Number of Participants With Treatment-Emergent Adverse Events by Severity (Palbociclib-Related)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. Palbociclib-related TEAEs were determined by the investigator.
Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
Number of Participants With Serious Adverse Events (All Causalities and Palbociclib-Related)
An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Palbociclib-related SAEs were determined by the investigator.
Time frame: Baseline up to 28 days after last dose of study treatment, an average of 14 months
Percentage of Participants With Complete Response and Partial Response
Tumor response assessments were evaluated as per local guidelines by investigators and were collected in the CRF. No response confirmation was applied.
Time frame: Baseline and per routine clinical practice to time of last dose of study treatment, an average of 1 year
The Objective Response Rate (ORR)
The tumor response was based on the response reported by investigator per local practice. No response confirmation was applied. ORR was defined as the percentage of participants with complete response or partial response relative to all as-treated population.
Time frame: Baseline and per routine clinical practice to time of last dose of study treatment, an average of 1 year
EQ-5D Health Utility Index Score
The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The first part was a 5 item questionnaire designed to assess health status in terms of a single index value or utility score. It consisted of 5 descriptors of current health state (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). A respondent was asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment. The answers given to the 5 descriptors permit to find 243 unique health states which can be converted into a single EQ-5D index value by published algorithms. For the EQ-5D index, published weights are available that allow for the creation of a summary score ranging from -0.594 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health.
Time frame: The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.
Change From Baseline in EQ-5D Health Utility Index Score
The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The first part was a 5 item questionnaire designed to assess health status in terms of a single index value or utility score. It consisted of 5 descriptors of current health state (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). A respondent was asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment. The answers given to the 5 descriptors permit to find 243 unique health states which can be converted into a single EQ-5D index value by published algorithms. For the EQ-5D index, published weights are available that allow for the creation of a summary score ranging from -0.594 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health.
Time frame: The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.
EQ-VAS Score
The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The second part consisted of a visual analogue scale (the EuroQol-visual analogue scale \[EQ-VAS\]). The respondent's self-rated health was assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state)
Time frame: The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.
Change From Baseline in EQ-VAS Score
The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The second part consisted of a visual analogue scale (the EuroQol-visual analogue scale \[EQ-VAS\]). The respondent's self-rated health was assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state)
Time frame: The descriptive analysis was carried out on Day 1 of each cycle (cycle 1 to cycle 38), at end of treatment (EOT) and end of study (EOS), up to 3 years. Cycle 1 Day 1 is taken to be baseline.
| Milestone | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort |
|---|---|---|
| Started | 100 | 152 |
| Completed | 66 | 47 |
| Not completed | 34 | 105 |
| Withdrew: Death | 0 | 3 |
| Withdrew: Global deterioration of health status | 1 | 8 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Objective progression or relapse | 24 | 83 |
| Withdrew: Not defined | 0 | 2 |
| Withdrew: Withdrawal by participant | 6 | 3 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Adverse events not related to study drug | 1 | 2 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as treatment emergent adverse events (TEAEs). AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Palbociclib+LetrozoleTotal |
|---|---|---|---|
| Participants with adverse events | 92 | 152 | 244 |
| Participants with serious adverse events | 18 | 45 | 63 |
| Participants with grade 3 or 4 adverse events | 69 | 124 | 193 |
| Participants with grade 5 adverse events | 3 | 7 | 10 |
| Participants discontinued due to adverse events | 2 | 9 | 11 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.
| Participants | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Palbociclib+Letrozole Total |
|---|---|---|---|
| Grade 1 | 7 | 11 | 18 |
| Grade 2 | 16 | 16 | 32 |
| Grade 3 | 49 | 105 | 154 |
| Grade 4 | 17 | 13 | 30 |
| Grade 5 | 3 | 7 | 10 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Palbociclib-related TEAEs were determined by the investigator.
| Participants | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Palbociclib+Letrozole Total |
|---|---|---|---|
| Participants with adverse events | 80 | 143 | 223 |
| Participants with serious adverse events | 8 | 12 | 20 |
| Participants with grade 3 or 4 adverse events | 64 | 108 | 172 |
| Participants with grade 5 adverse events | 0 | 1 | 1 |
| Participants discontinued due to adverse events | 1 | 4 | 5 |
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as TEAE. AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. Palbociclib-related TEAEs were determined by the investigator.
| Participants | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Palbociclib+Letrozole Total |
|---|---|---|---|
| Grade 1 | 6 | 21 | 27 |
| Grade 2 | 10 | 14 | 24 |
| Grade 3 | 49 | 93 | 142 |
| Grade 4 | 15 | 14 | 29 |
| Grade 5 | 0 | 1 | 1 |
An SAE was any untoward medical occurrence at any dose that resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect. Palbociclib-related SAEs were determined by the investigator.
| Participants | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Palbociclib+Letrozole Total |
|---|---|---|---|
| All-causality | 18 | 45 | 63 |
| Palciclib-Related | 8 | 12 | 20 |
Tumor response assessments were evaluated as per local guidelines by investigators and were collected in the CRF. No response confirmation was applied.
| Percentage of evaluable participants | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Palbociclib+Letrozole Total |
|---|---|---|---|
| Percentage of participants with complete response | 1.0 | 1.3 | 1.2 |
| Percentage of participants with partial response | 28.0 | 11.8 | 18.3 |
The tumor response was based on the response reported by investigator per local practice. No response confirmation was applied. ORR was defined as the percentage of participants with complete response or partial response relative to all as-treated population.
| Percentage of evaluable participants | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Palbociclib+Letrozole Total |
|---|---|---|---|
| The Objective Response Rate (ORR) | 29.0 (20.4 to 38.9) | 13.2 (8.2 to 19.6) | 19.4 (14.7 to 24.9) |
The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The first part was a 5 item questionnaire designed to assess health status in terms of a single index value or utility score. It consisted of 5 descriptors of current health state (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). A respondent was asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment. The answers given to the 5 descriptors permit to find 243 unique health states which can be converted into a single EQ-5D index value by published algorithms. For the EQ-5D index, published weights are available that allow for the creation of a summary score ranging from -0.594 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health.
| Scores on a scale | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort |
|---|---|---|
| Cycle 1 Day 1 | — | 0.786 ± 0.171 |
| Cycle 2 Day 1 | — | 0.798 ± 0.187 |
| Cycle 3 Day 1 | — | 0.798 ± 0.169 |
| Cycle 4 Day 1 | — | 0.836 ± 0.172 |
| Cycle 5 Day 1 | — | 0.838 ± 0.153 |
| Cycle 6 Day 1 | — | 0.825 ± 0.185 |
| Cycle 7 Day 1 | — | 0.818 ± 0.167 |
| Cycle 8 Day 1 | — | 0.831 ± 0.169 |
| Cycle 9 Day 1 | — | 0.845 ± 0.149 |
| Cycle 10 Day 1 | — | 0.840 ± 0.162 |
| Cycle 11 Day 1 | — | 0.820 ± 0.193 |
| Cycle 12 Day 1 | — | 0.810 ± 0.188 |
| Cycle 13 Day 1 | — | 0.839 ± 0.183 |
| Cycle 14 Day 1 | — | 0.842 ± 0.159 |
| Cycle 15 Day 1 | — | 0.840 ± 0.138 |
| Cycle 16 Day 1 | — | 0.830 ± 0.182 |
| Cycle 17 Day 1 | — | 0.837 ± 0.163 |
| Cycle 18 Day 1 | — | 0.836 ± 0.182 |
| Cycle 19 Day 1 | — | 0.848 ± 0.179 |
| Cycle 20 Day 1 | — | 0.853 ± 0.143 |
| Cycle 21 Day 1 | — | 0.868 ± 0.132 |
| Cycle 22 Day 1 | — | 0.864 ± 0.132 |
| Cycle 23 Day 1 | — | 0.846 ± 0.170 |
| Cycle 24 Day 1 | — | 0.864 ± 0.135 |
| Cycle 25 Day 1 | — | 0.861 ± 0.138 |
| Cycle 26 Day 1 | — | 0.869 ± 0.143 |
| Cycle 27 Day 1 | — | 0.884 ± 0.140 |
| Cycle 28 Day 1 | — | 0.876 ± 0.152 |
| Cycle 29 Day 1 | — | 0.852 ± 0.147 |
| Cycle 30 Day 1 | — | 0.857 ± 0.160 |
| Cycle 31 Day 1 | — | 0.784 ± 0.278 |
| Cycle 32 Day 1 | — | 0.864 ± 0.163 |
| Cycle 33 Day 1 | — | 0.870 ± 0.140 |
| Cycle 34 Day 1 | — | 0.838 ± 0.160 |
| Cycle 35 Day 1 | — | 0.905 ± 0.128 |
| Cycle 36 Day 1 | — | 0.779 ± 0.294 |
| Cycle 37 Day 1 | — | 0.854 ± 0.170 |
| Cycle 38 Day 1 | — | 0.810 ± 0.269 |
| End of Treatment (EOT) | — | 0.698 ± 0.324 |
| End of Study (EOS) | — | 0.770 ± 0.247 |
The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The first part was a 5 item questionnaire designed to assess health status in terms of a single index value or utility score. It consisted of 5 descriptors of current health state (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). A respondent was asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment. The answers given to the 5 descriptors permit to find 243 unique health states which can be converted into a single EQ-5D index value by published algorithms. For the EQ-5D index, published weights are available that allow for the creation of a summary score ranging from -0.594 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health.
| Scores on a scale | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort |
|---|---|---|
| Baseline (Cycle 1 Day 1) | — | 0.786 ± 0.171 |
| Cycle 2 Day 1 | — | 0.013 ± 0.172 |
| Cycle 3 Day 1 | — | 0.021 ± 0.156 |
| Cycle 4 Day 1 | — | 0.052 ± 0.175 |
| Cycle 5 Day 1 | — | 0.052 ± 0.181 |
| Cycle 6 Day 1 | — | 0.037 ± 0.214 |
| Cycle 7 Day 1 | — | 0.033 ± 0.173 |
| Cycle 8 Day 1 | — | 0.050 ± 0.156 |
| Cycle 9 Day 1 | — | 0.057 ± 0.165 |
| Cycle 10 Day 1 | — | 0.049 ± 0.192 |
| Cycle 11 Day 1 | — | 0.034 ± 0.225 |
| Cycle 12 Day 1 | — | 0.029 ± 0.235 |
| Cycle 13 Day 1 | — | 0.058 ± 0.203 |
| Cycle 14 Day 1 | — | 0.058 ± 0.188 |
| Cycle 15 Day 1 | — | 0.062 ± 0.184 |
| Cycle 16 Day 1 | — | 0.051 ± 0.182 |
| Cycle 17 Day 1 | — | 0.059 ± 0.165 |
| Cycle 18 Day 1 | — | 0.060 ± 0.181 |
| Cycle 19 Day 1 | — | 0.061 ± 0.179 |
| Cycle 20 Day 1 | — | 0.069 ± 0.197 |
| Cycle 21 Day 1 | — | 0.082 ± 0.169 |
| Cycle 22 Day 1 | — | 0.076 ± 0.081 |
| Cycle 23 Day 1 | — | 0.073 ± 0.193 |
| Cycle 24 Day 1 | — | 0.085 ± 0.183 |
| Cycle 25 Day 1 | — | 0.083 ± 0.192 |
| Cycle 26 Day 1 | — | 0.052 ± 0.140 |
| Cycle 27 Day 1 | — | 0.063 ± 0.129 |
| Cycle 28 Day 1 | — | 0.071 ± 0.153 |
| Cycle 29 Day 1 | — | 0.056 ± 0.126 |
| Cycle 30 Day 1 | — | 0.055 ± 0.122 |
| Cycle 31 Day 1 | — | -0.013 ± 0.243 |
| Cycle 32 Day 1 | — | 0.049 ± 0.099 |
| Cycle 33 Day 1 | — | 0.060 ± 0.098 |
| Cycle 34 Day 1 | — | 0.026 ± 0.123 |
| Cycle 35 Day 1 | — | 0.092 ± 0.134 |
| Cycle 36 Day 1 | — | -0.036 ± 0.240 |
| Cycle 37 Day 1 | — | 0.011 ± 0.107 |
| Cycle 38 Day 1 | — | -0.012 ± 0.232 |
| End of Treatment (EOT) | — | -0.147 ± 0.239 |
| End of Study (EOT) | — | -0.022 ± 0.228 |
The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The second part consisted of a visual analogue scale (the EuroQol-visual analogue scale \[EQ-VAS\]). The respondent's self-rated health was assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state)
| Scores on a scale | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort |
|---|---|---|
| Cycle 1 Day 1 | — | 76.9 ± 16.00 |
| Cycle 2 Day 1 | — | 77.3 ± 15.29 |
| Cycle 3 Day 1 | — | 77.4 ± 15.52 |
| Cycle 4 Day 1 | — | 80.3 ± 14.17 |
| Cycle 5 Day 1 | — | 80.4 ± 14.66 |
| Cycle 6 Day 1 | — | 79.8 ± 15.77 |
| Cycle 7 Day 1 | — | 79.7 ± 14.81 |
| Cycle 8 Day 1 | — | 80.1 ± 13.75 |
| Cycle 9 Day 1 | — | 80.9 ± 14.54 |
| Cycle 10 Day 1 | — | 81.2 ± 14.75 |
| Cycle 11 Day 1 | — | 81.0 ± 14.60 |
| Cycle 12 Day 1 | — | 81.3 ± 13.99 |
| Cycle 13 Day 1 | — | 80.4 ± 14.37 |
| Cycle 14 Day 1 | — | 80.9 ± 13.72 |
| Cycle 15 Day 1 | — | 82.1 ± 12.24 |
| Cycle 16 Day 1 | — | 82.9 ± 12.93 |
| Cycle 17 Day 1 | — | 83.1 ± 12.89 |
| Cycle 18 Day 1 | — | 83.1 ± 12.31 |
| Cycle 19 Day 1 | — | 83.7 ± 12.75 |
| Cycle 20 Day 1 | — | 84.5 ± 12.10 |
| Cycle 21 Day 1 | — | 85.3 ± 12.03 |
| Cycle 22 Day 1 | — | 85.5 ± 11.77 |
| Cycle 23 Day 1 | — | 84.1 ± 14.30 |
| Cycle 24 Day 1 | — | 85.6 ± 12.78 |
| Cycle 25 Day 1 | — | 84.9 ± 12.89 |
| Cycle 26 Day 1 | — | 87.6 ± 11.08 |
| Cycle 27 Day 1 | — | 88.1 ± 9.88 |
| Cycle 28 Day 1 | — | 87.5 ± 9.32 |
| Cycle 29 Day 1 | — | 88.5 ± 9.98 |
| Cycle 30 Day 1 | — | 91.5 ± 6.97 |
| Cycle 31 Day 1 | — | 88.1 ± 12.26 |
| Cycle 32 Day 1 | — | 91.0 ± 8.06 |
| Cycle 33 Day 1 | — | 88.6 ± 10.61 |
| Cycle 34 Day 1 | — | 91.0 ± 8.06 |
| Cycle 35 Day 1 | — | 90.0 ± 11 |
| Cycle 36 Day 1 | — | 87.5 ± 14.84 |
| Cycle 37 Day 1 | — | 91.5 ± 7.42 |
| Cycle 38 Day 1 | — | 91.5 ± 0.71 |
| End of Treatment (EOT) | — | 73.6 ± 23.88 |
| End of Study (EOS) | — | 77.3 ± 18.99 |
The EuroQol-5D (EQ-5D) (version 3L) consisted of 2 parts. The second part consisted of a visual analogue scale (the EuroQol-visual analogue scale \[EQ-VAS\]). The respondent's self-rated health was assessed on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state)
| Scores on a scale | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort |
|---|---|---|
| Baseline (Cycle 1 Day 1) | — | 76.9 ± 16.00 |
| Cycle 2 Day 1 | — | 0.4 ± 13.28 |
| Cycle 3 Day 1 | — | 0.3 ± 13.47 |
| Cycle 4 Day 1 | — | 2.9 ± 13.06 |
| Cycle 5 Day 1 | — | 3.2 ± 14.70 |
| Cycle 6 Day 1 | — | 2.3 ± 15.53 |
| Cycle 7 Day 1 | — | 2.0 ± 15.79 |
| Cycle 8 Day 1 | — | 2.4 ± 13.64 |
| Cycle 9 Day 1 | — | 2.3 ± 12.54 |
| Cycle 10 Day 1 | — | 2.4 ± 14.44 |
| Cycle 11 Day 1 | — | 2.1 ± 13.72 |
| Cycle 12 Day 1 | — | 2.9 ± 13.76 |
| Cycle 13 Day 1 | — | 2.1 ± 13.84 |
| Cycle 14 Day 1 | — | 2.3 ± 14.00 |
| Cycle 15 Day 1 | — | 3.5 ± 12.12 |
| Cycle 16 Day 1 | — | 3.7 ± 13.82 |
| Cycle 17 Day 1 | — | 3.9 ± 12.77 |
| Cycle 18 Day 1 | — | 4.5 ± 11.86 |
| Cycle 19 Day 1 | — | 4.6 ± 11.69 |
| Cycle 20 Day 1 | — | 5.5 ± 12.58 |
| Cycle 21 Day 1 | — | 6.0 ± 11.77 |
| Cycle 22 Day 1 | — | 5.0 ± 9.71 |
| Cycle 23 Day 1 | — | 4.4 ± 13.20 |
| Cycle 24 Day 1 | — | 4.6 ± 11.93 |
| Cycle 25 Day 1 | — | 4.3 ± 10.71 |
| Cycle 26 Day 1 | — | 4.4 ± 8.63 |
| Cycle 27 Day 1 | — | 5.6 ± 6.26 |
| Cycle 28 Day 1 | — | 5.5 ± 8.24 |
| Cycle 29 Day 1 | — | 5.9 ± 7.57 |
| Cycle 30 Day 1 | — | 6.5 ± 7.88 |
| Cycle 31 Day 1 | — | 4.3 ± 11.52 |
| Cycle 32 Day 1 | — | 7.3 ± 10.59 |
| Cycle 33 Day 1 | — | 7.1 ± 12.75 |
| Cycle 34 Day 1 | — | 7.6 ± 6.68 |
| Cycle 35 Day 1 | — | 6.6 ± 9.27 |
| Cycle 36 Day 1 | — | 3.5 ± 8.22 |
| Cycle 37 Day 1 | — | 10.3 ± 1.71 |
| Cycle 38 Day 1 | — | 9.0 ± 4.24 |
| End of Treatment (EOT) | — | -3.2 ± 22.24 |
| End of Study (EOS) | — | 0.4 ± 19.72 |
Collected over AEs (serious and non-serious) were recorded on the CRF from the time the participant had taken at least 1 dose of investigational product through and including 28 calendar days after the last administration of the study treatment, an average of 14 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Palbociclib+Letrozole India Cohort | 3/100 (3%) | 18/100 (18%) | 85/100 (85%) |
| Palbociclib+Letrozole Australia Cohort | 7/152 (4.6%) | 45/152 (29.6%) | 151/152 (99.3%) |
| Event | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/100 | 0/152 |
| Disease progressionGeneral disorders | 2/100 | 6/152 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/100 | 5/152 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/100 | 3/152 |
| VomitingGastrointestinal disorders | 3/100 | 0/152 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 3/100 | 1/152 |
| Lower respiratory tract infectionInfections and infestations | 2/100 | 1/152 |
| Urinary tract infectionInfections and infestations | 1/100 | 3/152 |
| Abdominal painGastrointestinal disorders | 0/100 | 2/152 |
| Abdominal pain upperGastrointestinal disorders | 0/100 | 2/152 |
| Event | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 57/100 | 110/152 |
| FatigueGeneral disorders | 9/100 | 99/152 |
| NauseaGastrointestinal disorders | 3/100 | 57/152 |
| Upper respiratory tract infectionInfections and infestations | 5/100 | 57/152 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/100 | 52/152 |
| DiarrhoeaGastrointestinal disorders | 7/100 | 51/152 |
| HeadacheNervous system disorders | 4/100 | 47/152 |
| Back painMusculoskeletal and connective tissue disorders | 9/100 | 35/152 |
| Hot flushVascular disorders | 0/100 | 35/152 |
| Mouth ulcerationGastrointestinal disorders | 3/100 | 34/152 |
The analysis population included all participants who received at least 1 dose of palbociclib treatment.
| Age, Categorical(Participants) | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 71 | 107 | 178 |
| >=65 years | 29 | 45 | 74 |
| Sex: Female, Male(Participants) | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Total |
|---|---|---|---|
| Female | 100 | 152 | 252 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Palbociclib+Letrozole India Cohort | Palbociclib+Letrozole Australia Cohort | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 100 | 12 | 112 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 0 | 130 | 130 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 9 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2016 to primary completion in Jul 2019, 40 months.
Results were first posted in Oct 2020, 1 year 2 months after primary completion.
Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 40 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Palbociclib · Letrozole